These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37179465)

  • 21. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
    Kuno T; Ueyama H; Fujisaki T; Briasouli A; Takagi H; Briasoulis A
    Am J Cardiol; 2020 Apr; 125(8):1187-1193. PubMed ID: 32081366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology.
    Perrone-Filardi P; Paolillo S; Agostoni P; Basile C; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Indolfi C; Sinagra G
    Eur J Intern Med; 2022 Aug; 102():8-16. PubMed ID: 35469709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction.
    Raschi E; Diemberger I; Sabatino M; Poluzzi E; De Ponti F; Potena L
    Expert Opin Pharmacother; 2022 Feb; 23(3):303-320. PubMed ID: 35050813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
    Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
    Kapelios CJ; Lainscak M; Savarese G; Laroche C; Seferovic P; Ruschitzka F; Coats A; Anker SD; Crespo-Leiro MG; Filippatos G; Piepoli MF; Rosano G; Zanolla L; Aguiar C; Murin J; Leszek P; McDonagh T; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2019 Nov; 21(11):1383-1397. PubMed ID: 31132222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
    Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
    J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and emerging drug targets in heart failure treatment.
    Ghionzoli N; Gentile F; Del Franco AM; Castiglione V; Aimo A; Giannoni A; Burchielli S; Cameli M; Emdin M; Vergaro G
    Heart Fail Rev; 2022 Jul; 27(4):1119-1136. PubMed ID: 34273070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction.
    Antol DD; Casebeer AW; DeClue RW; Stemkowski S; Russo PA
    Adv Ther; 2018 Jun; 35(6):785-795. PubMed ID: 29777521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
    Yang M; Butt JH; Kondo T; Jering KS; Docherty KF; Jhund PS; de Boer RA; Claggett BL; Desai AS; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Langkilde AM; Martinez FA; Petersson M; Shah SJ; Vaduganathan M; Wilderäng U; Solomon SD; McMurray JJV
    Eur J Heart Fail; 2022 Dec; 24(12):2307-2319. PubMed ID: 36342375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
    Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.
    Tsutsui H
    Pharmacol Ther; 2022 Oct; 238():108185. PubMed ID: 35413307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in pharmacological treatment of heart failure.
    Iacoviello M; Palazzuoli A; Gronda E
    Eur J Clin Invest; 2021 Nov; 51(11):e13624. PubMed ID: 34043809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.